^
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 5 days
HER-2 negative
Gastric Adenocarcinoma
cisplatin + paclitaxel + capecitabine
Sensitive: C3 – Early Trials
Asia Pac J Clin Oncol - 1 week
miR-200b underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-199b overexpression +miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-199b overexpression
Gastric Cancer
5-fluorouracil
Sensitive: D – Preclinical
DNA Cell Biol - 2 weeks
miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-200b underexpression + miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
HER-2 positive
Gastric Cancer
trastuzumab + ramucirumab + ALX148
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
FGFR3 amplification
Gastric Adenocarcinoma
pazopanib
Sensitive: C4 – Case Studies
Clin Case Rep - 3 weeks
ICAM1 overexpression
Gastric Cancer
AIC100
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
CLDN18.2 positive
Gastric Cancer
CLDN18.2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
disitamab vedotin
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
cisplatin + capecitabine
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
TCF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FP
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FOLFIRI
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DP
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel + capecitabine
Sensitive: A2 - Guideline
TMB-H
Gastric Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FLOT
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
HER-2 positive
GastroEsophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
docetaxel + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
IP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline